نتایج جستجو برای: jak2 v617f

تعداد نتایج: 4704  

Journal: :Folia histochemica et cytobiologica 2011
Bożena Sokołowska Aleksandra Nowaczyńska Ksenia Bykowska Sylwia Chocholska Katarzyna Wejksza Adam Walter-Croneck Tomasz Gromek Anna M Kowalska Martyna Kandefer-Szerszeń Anna Dmoszyńska

The recently discovered JAK2 V617F point mutation, found in 50-60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothromb...

Journal: :Blood 2009
Jonathan R Lambert Tamara Everington David C Linch Rosemary E Gale

In essential thrombocythemia (ET), the JAK2-V617F mutation is usually restricted to a subpopulation of neutrophils and platelets, and production of JAK2 wild-type (WT) platelets is not suppressed. Nonmutated precursor cells may, therefore, be susceptible to the acquisition of further JAK2 mutations. We used a common single nucleotide polymorphism (SNP) in the JAK2 coding sequence to genotype V6...

Journal: :American journal of clinical pathology 2007
Angela Y C Tan David A Westerman Alexander Dobrovic

The point mutation 1849 (GT) V617F in the JAK2 gene occurs at high frequency in several chronic myeloproliferative diseases. Although a number of V617F mutation detection methods have been described, few are readily implemented in a diagnostic setting. We developed a simple and sensitive allelespecific competitive blocker polymerase chain reaction (ACB-PCR) assay to detect the V617F mutation. D...

2013
Xiaobo Wan Yue Ma Christopher L. McClendon Lily Jun-shen Huang Niu Huang

The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis. JAK2 kinase activity is negatively regulated by its pseudokinase domain (JH2), where the gain-of-function mutation V617F that causes myeloproliferative neoplasms resides. In the absence of a crystal stru...

الهی, فاضل, جهانگیرپور, محمد علی, رضوانی, حمید, شریفیان, رمضانعلی, شمسیان, محمد علی, فراهانی, کبری, قدیانی, مجتبی, میرمنگره, هاجر, پورفتح‌اله, علی‌اکبر, پوپک, بهزاد, کاویانی, سعید, کیهانی, منوچهر, یوسفیان, ابوالفضل,

  چکید ه   سابقه و هدف   جهش سوماتیک نقطه‌ای در ژن پروتئین تیروزین کیناز JAK2 ( JAK2 V617F ) باعث جابجایی G با T در اگزون 12 ژن JAK2 می‌شود که منجر به فعالیت خودبخودی پروتئین JAK2 و انتقال پیام غیر وابسته به سیتوکاین می‌گردد و در نتیجه باعث تکثیر کلونال پیش‌سازهای خونساز در MPNs می‌شود. با توجه به این که تاکنون در ایران، هیچ گزارشی از جهش JAK2 V617F و اهمیت آن در تشخیص بیماران مبتلا به نئوپلاسم...

Journal: :American journal of clinical pathology 2009
Milena Cankovic Lisa Whiteley Robert C Hawley Richard J Zarbo Dhananjay Chitale

The presence of the JAK2 V617F mutation is now part of clinical diagnostic algorithms, and JAK2 status is routinely assessed when BCR/ABL- chronic myeloproliferative neoplasms (MPNs) are suspected. The aim of this study was to evaluate performance of 3 screening and 1 quantitative method for JAK2 V617F detection. For the study, 43 samples (27 bone marrow aspirates and 16 peripheral blood sample...

2016
Emilie Leroy Alexandra Dusa Didier Colau Amir Motamedi Xavier Cahu Céline Mouton Lily J. Huang Andrew K. Shiau Stefan N. Constantinescu

The mechanisms by which JAK2 is activated by the prevalent pseudokinase (JH2) V617F mutation in blood cancers remain elusive. Via structure-guided mutagenesis and transcriptional and functional assays, we identify a community of residues from the JH2 helix αC, SH2-JH2 linker and JH1 kinase domain that mediate V617F-induced activation. This circuit is broken by altering the charge of residues al...

2015
Peijin Zhang Yanyan Zhang Jing Zhang Hui Wang He Ma Wei Wang Xiuyin Gao Hao Xu Zhaojun Lu

Myeloproliferative neoplasms (MPNs) are the leading cause of Budd-Chiari syndrome (BCS), and the C allele of JAK2 rs4495487 was reported to be an additional candidate locus that contributed to MPNs. In the present study, we examined the role of JAK2 rs4495487 in the etiology and clinical presentation of Chinese BCS patients. 300 primary BCS patients and 311 healthy controls were enrolled to eva...

Journal: :Journal of clinical pathology 2011
Ilka Warshawsky Frank Mularo

AIMS Detecting low-level clinically significant cancer-relevant somatic mutations can be difficult. Several technologies exist for detecting minority mutations. One method is locked nucleic acid (LNA) PCR. In this study, LNA probes were used to enhance the sensitivity for detecting FLT3 D835/I836 tyrosine kinase domain (TKD) mutations, the JAK2 V617F mutation and insertion mutations in the nucl...

2013
Erhan Tatar Adam Uslu Ahmet Aykas Funda Tasli Ozgur Oztekin Gulsum Akgun Cagliyan

BACKGROUND Recurrent episodes of venous thrombosis have been closely correlated with JAK2 V617F mutation. Upto date, JAK2 gene mutation has not been defined as a prothrombic risk factor in renal transplant recipients. Herein; we present a case of portosplenic vein thrombosis in a primary renal transplant recipient with JAK2 V617F mutation who had no history of prior venous thromboembolism or th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید